min-') and was greater than the renal clearance (0.8 ± 0.8 ml min-'). The peritoneal concentration rose to 91 ± 29 ,ug ml-' at 6 h, which was 0.61 ± 0.17 of the serum concentration. A 3-g intravenous dose of ceftizoxime given every 48 h would result in adequate activity against most susceptible organisms, but more frequent dosing may be necessary for less susceptible organisms.
Continuous ambulatory peritoneal dialysis (CAPD) is a self-dialysis procedure which uses the continuous presence of peritoneal dialysis solution in the peritoneal cavity, except during periods of drainage and filling with fresh solution (10) . The most dramatic complication of CAPD is peritonitis, usually by gram-negative or grampositive bacteria (8) . Ceftizoxime is a semisynthetic cephalosporin with a spectrum of activity against many of these bacteria (7) . The purpose of this study was to examine the pharmacokinetics and peritoneal equilibration of ceftizoxime in patients undergoing CAPD.
MATERIALS AND METHODS
Twelve patients (five males and seven females) with end-stage renal failure undergoing CAPD gave written, informed consent to participate in this study. Patients requiring systemic antibiotic therapy or who had a known allergy to cephalosporins or penicillins, anemia with a hemoglobin concentration of <6 g/dl, or hepatic disease were excluded. Each patient had a physical examination before the study and a hematological and biochemical profile, urinalysis (when possible), and an electrocardiogram before and after they were studied.
All patients had an indwelling Tenckhoff catheter already in place. A three-way stopcock was placed between the catheter and the tubing line from the peritoneal dialysate bag. A 50-ml plastic syringe was attached to the third prong of the stopcock. (Ae-') v (1 -e-"m)/(1 -e"=) + (Be-I) ( 1 -e 'I')/(I -e0), where C is the serum concentration at any time t, n is the number of doses, and r is the dosage interval.
RESULTS
The kinetic parameters derived by applying a
two-compartment open model to the fitted serum concentraijon-time data are shown in Table   1 . The overall serum clearance of ceftizoxime was 17.1 ± 7.4 ml min-'. This was composed of the renal clearance of 0.8 ± 0.8 ml mimf', the peritoneal clearance of 2.8 ± 0.7 ml min-, and the nonrenal clearce. Theperitoneal clearance of ceftizoxime was lower than that of either urea (5.0 ± 0.5 ml min-') or creatinine (4.4 ± 0.5 ml min-'). Whereas in patients with normal renal function the nonrenal clearance only contributed approximately 22% to the overall serum clearance (2) , nonrenal clearance contributed approximately 79% to the overall serum clearance in patients with end-stage renal disease treated with CAPD.
The serum ceftizoxime concentrations and corresponding peritoneal dialysate concentrations are presented in Table 2 . Although the peritoneal dialysate concentrations did not rise to equal the serum concentration of ceftizoxime, the concentrations did rise to the extent that the peritoneal dialysate-to-serum ration was 0.61 ± 0.17 at 6 h.
Simulation of multiple 3-g doses at equally spaced intervals revealed that a dosage interval Wg ml-' and a trough serum concentration of 7
The adverse effects of the drug were li. 4 to chills experienced during infusion of the drug in three patients. Accidental disconnectioo of the three-way stopcock from the peritoneal catheter with spillage of some dialysate occurred in one patient, but this did not result in infection. The patient's data were excluded frm analysis when calculating the peritoneal clearance of the drug. DISCUSSION Ceftizoxime is a cephalosporin antibiotic which is eliminated primarily through the ineys by glomerular ifitration, with minimal net tubular transport in subjects with nomal renal function. In hemodialysis patients with endstage renal disease who were adminstered the drug in a nonbemodialysis period, drug disposition was described by a three-compamnt model with a half-life of 19.3 ± 7.5 h (harnnic mean) (2) . This is somewhat longer than the halflife of the drug in our population of end-stage renal disease patients treated by CAPM (9.7 ± 5.1 h). The factors which may have'Joad to this discrepancy include the presence of an ongoing additional clearance mechanism, i.e., peritoneal dialysis, and the shorter samping time of 6 h corresponding to the usual dwell time of CAPD. Unfortunately, prolontion f te sping Priod may have een desiable from a modeling point of view, but it would not have been representative ofthe process ivolved in CAPD. Continuation ot the study to include later cycles of CAPD) would likely have led to alteration in kinetics of the drug due to the change in the diffusion gradient across the peritoneal mem-brane and hence a decreased peritoneal clearance.
Ceftizoxime appeared in the peritoneal dialysate within 0.25 h of commencement of infusion of the drug and reached a plateau concentration at 5 h. The ratio of the peritoneal dialysate to serum concentrations reached a maximum of 0.61 during the 6 h of the study and is greater than that seen after intravenous administration of cefazolin (1) . Peritoneal dialysis contributed a clearance of 2.8 ± 0.7 ml min-' (15% of total body clearance) in the CAPD patient, which is similar to that seen for cefazolin or cephalexin (1) .
In vitro studies have shown that the minimum concentration of ceftizoxime inhibiting 90% of strains tested is -0.2 ,ug ml-' for Haemophilus influenzae, Neisseria gonorrhoeae, Escherichia coli, Streptococcus pneumoniae, groups A, B, C, and G streptococci, Klebsiella pneumoniae, non-beta-lactamase-producing Salmonella species, and Proteus mirabilis. The minimum concentrations of ceftizoxime inhibiting 90%o of the less susceptible species are: Serratia marcescens, 12.5 pug ml-; Bacteriodes fragilis, 4 to 25 ,ug ml-' and Pseudomonas aeruginosa, 16 to 100 ,ugg ml-' (3) (4) (5) (6) . The concentration of ceftizoxime attained in the peritoneal dialysate at 0.25 h (Table 2) should provide adequate antibacterial activity against most susceptible organisms, but even those concentrations attained after 6 h may not provide adequate activity against less susceptible bacteria. The presence of adequate inhibitory concentrations does not necessarily forecast therapeutic success, since the size of the inoculum of the less susceptible organisms would appear to influence the outcome of therapy (4) .
Since ceftizoxime is eliminated primarily by the kidneys, alteration in dosage schedules is necessary when treating patients with renal failure. The dosage predictions allow formulation of the peak and trough serum concentrations that would be attained in a steady state during continuous peritoneal dialysis with 6-h dwell times. It is very difficult to predict what the peritoneal dialysate concentrations would be, since they would be dependent upon the relations between the time of administration of the drug and the dwell time of the dialysate exchanges. However, if the dwell times were kept constant at 6 h, it would be reasonable to assume that at the end of any given 6-h dwell time, the peritoneal concentration may be approximately 60%o of the serum concentration. Therefore, the peritoneal dialysate concentration could vary widely and possibly drop below the therapeutic concentration for long periods of time if the drug were given every 48 h (peak and trough serum concentrations, 495 ,ug ml-' and 7 ,ug ml-', respectively; calculated peak and trough peritoneal concentrations, 297
Ixg ml-' and 4.2 ,ug ml-', respectively) but would likely vary less and maintain therapeutic concentrations for longer periods if the drug were given every 12 h (peak and trough serum concentrations, 635 pug ml-' and 146 ,ug ml-', respectively; and calculated peak and trough peritoneal concentrations, 381 ,ug ml-' and 87.6 ,ug ml-', respectively).
